gefitinib has been researched along with bupropion in 4 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (bupropion) | Trials (bupropion) | Recent Studies (post-2010) (bupropion) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 3,392 | 755 | 1,329 |
| Protein | Taxonomy | gefitinib (IC50) | bupropion (IC50) |
|---|---|---|---|
| Acetylcholine receptor subunit alpha | Homo sapiens (human) | 5.2693 | |
| Acetylcholine receptor subunit gamma | Homo sapiens (human) | 5.2693 | |
| Integrin alpha-5 | Homo sapiens (human) | 1.8 | |
| Acetylcholine receptor subunit beta | Homo sapiens (human) | 5.2693 | |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | 0.9373 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.2003 | |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | 1.2028 | |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | 1.367 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 1.9983 | |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | 7.9 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | 0.0135 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.0848 | |
| Acetylcholine receptor subunit delta | Homo sapiens (human) | 5.2693 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for gefitinib and bupropion
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for gefitinib and bupropion
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |